Navigation Links
AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing
Date:11/19/2009

hold. This is exactly what we did with our Alzheimer's vaccination program and the outcome in the Phase I trials at this stage enabled us to make this decision earlier than we expected and to offer a booster vaccination to the AD02-treated patients. Finally, we can also redirect our resources which will now be available for our other vaccination programs." AFFiRiS AG can also invest all of the EUR 10 million, paid by licensing partner GSK Biologicals as a milestone payment for the positive completion of the Phase I studies, in the other R&D programs.

The vaccine development program of AFFiRiS is based on the company's AFFITOME(R) technology, which also delivered the vaccines tested so far. Also based on this technology are six other vaccination programs being developed by AFFiRiS AG, which target, among other indications, Parkinson's disease and atherosclerosis.

About AFFiRiS AG (status November 2009):

Based on proprietary patent positions, AFFiRiS has developed tailored peptide vaccines against Alzheimer's Disease, Parkinson's and four other diseases characterized by urgent medical requirement and attractive market volumes. Alzheimer's is the current lead indication and clinical Phase I trials have just been completed on two product candidates. AFFiRiS succeeded in attracting GlaxoSmithKline Biologicals as its licensing partner in October 2008. The contract contains provisions for (milestone-dependent) payments of up to EUR 430 million. Based on the successful completion of two clinical Phase I trials, a payment of EUR 10 million was made in October. AFFiRiS currently employs 60 highly-qualified staff at its premises on the St. Marx Campus in Vienna, Austria (http://www.affiris.com).


    Contact AFFiRiS AG:
    Mag. Agnes Meyer
    Karl-Farkas-Gasse 22
    T +43-1-798-15-75-3
    mailto:agnes.meyer@affiris.com
    '/>"/>
SOURCE AFFiRiS AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
2. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
3. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
4. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
5. Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
6. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
7. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 September 2009
8. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
9. Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
10. Bavarian Nordic A/S - Half Year Interim Report 2009
11. Arpida Reports Interim Results For Six Months to 30 June 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... The Board of Directors of BD (Becton, Dickinson ... quarterly dividend of 54.5 cents per common share payable on ... 2014. The indicated annual dividend rate is $2.18 per share. ... leading medical technology company that partners with customers and stakeholders ... health needs. Our innovative solutions are focused on improving drug ...
(Date:7/22/2014)...   BioTE Medical , a leading provider ... pellets, today announced the addition of Dr. ... Rouzier is joining the BioTE Medical Advisory Board ... Rouzier was residency trained in Family Medicine and ... certified emergency physician still practicing at a large ...
(Date:7/22/2014)... 22, 2014 The DNA Spectrum ... concise visual representation of history, migration, and culture. ... regaled by family history stories stemming from Europe. His ... "old country." Pictures and 8mm home movies painted an ... the family, and Steve ordered a test from DNA ...
(Date:7/22/2014)... Massachusetts e SHENZHEN , ... Co., LTD, (BGI Tech), una filiale di BGI, la ... lancio mondiale di un nuovo servizio di sequenziamento dell,intero ... di Complete Genomics. Complete Genomics, molto ... tecnologie di sequenziamento proprietarie con il 99.999% di precisione ...
Breaking Biology Technology:Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 2DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 4BGI Tech lancia un servizio di sequenziamento dell'intero esoma umano sulla piattaforma avanzata di Complete Genomics 2
... Inc., a leader in material science and polymer extrusions, ... The standard was developed by The Society for Automotive ... This certification is merely one indication of Zeus, increased ... working directly with more suppliers to design end products ...
... study, entitled Sustainable Value in Automobile Manufacturing, looks ... manufacturers worldwide between 1999 and 2007. It has ... School in Belfast, in partnership with researchers from ... for Futures Studies and Technology Assessment (IZT) in ...
... CAMBRIDGE, Mass., Oct. 29 Idenix Pharmaceuticals, Inc. (Nasdaq: ... discovery and development of drugs for the treatment of ... has decided not to exercise its option to license ... for the treatment of HCV. As a result, ...
Cached Biology Technology:Zeus Increases Its Presence in Aerospace Industry with AS9100 Certification 2North America automobile sector bottom of 'world sustainability league' 2North America automobile sector bottom of 'world sustainability league' 3Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV 2Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV 3
(Date:7/22/2014)... and you,re likely to find that the lunches and snacks ... of a study conducted by researchers at the Friedman School ... the Department of Public Health and Community Medicine at Tufts ... ahead of print in the Journal of the Academy ... author Jeanne Goldberg, Ph.D., R.D., a professor at the Friedman ...
(Date:7/22/2014)... immune cell widely believed to exacerbate chronic adult ... sclerosis (MS), can actually protect the brain from ... progression of neurodegenerative diseases, according to Cleveland Clinic ... Nature Communications . , The research team, led ... of Neurosciences at Cleveland Clinic,s Lerner Research Institute, ...
(Date:7/21/2014)... Middle East Respiratory Syndrome coronavirus (MERS-CoV) in the air ... virus. The work, published this week in mBio ... for Microbiology, indicates that further studies are needed to ... air. , MERS, a serious viral respiratory illness caused ... as of June 11, according to the World Health ...
Breaking Biology News(10 mins):Room for improvement in elementary school children's lunches and snacks from home 2Cleveland Clinic researchers discover neuroprotective role of immune cell 2Middle East Respiratory Syndrome coronavirus detected in the air of a Saudi Arabian camel barn 2
... a revolutionary approach to study microbes. Rather than isolating ... directly to environmental samples to obtain information about the ... habitat studied. The ocean is an ideal subject of ... equals that of all other living organisms on earth ...
... Representatives from the Midlands Consortium say they are ... has been chosen to host a new 1billion ... Midlands Consortium is comprised of the universities of ... all with extensive and complementary energy related research ...
... , Vancouver, B.C. - On Sept. 24, 2007, ... at the UBCM Pine Beetle Conference and will announce ... Beetle Program to help affected communities. Location: ... Canada Place Way, Vancouver, B.C. Date and ...
Cached Biology News:Metagenomics of the deep Mediterranean 2Midlands Consortium delighted to be chosen to host £1 billion energy institute 2Midlands Consortium delighted to be chosen to host £1 billion energy institute 3
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... to Human Cytokeratin TYPE II Reacts ... keratins. Including epidermal cell keratin of 86 ... and 67kD. Broad keratin reactivity is found ... Immunogen: Human epidermal ...
BD BioCoat Fibronectin 150 mm Culture Dishes...
Biology Products: